SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs Q3 earnings report is the dominant focus, with traders debating whether a strong report and raised guidance can overcome elevated expectations amid a broader AI-stock pullback. Bulls point to continued AI growth, while bears warn that a beat may not be enough to prevent profit-taking or valuation pressure.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Attention centers on Zevras quarterly results and the pending CHMP re-examination of MIPLYFFA, with the FDAs follow-up on celiprolol also viewed as a potential catalyst. Traders see U.S. MIPLYFFA growth as a support, but debate whether European regulators will reverse their earlier negative opinion, while some express frustration with management and the stocks volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anticipation for QUILT-2.005 topline results on ANKTIVA plus BCG in BCG-naive bladder cancer dominates discussion, with traders debating whether the data will support broader first-line use after ANKTIVAs expanded bladder-cancer approval. Many are bullish on the potential commercial expansion and upcoming earnings, while others cite execution and competition concerns and blame short selling for recent weakness.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a semiconductor selloff as traders question whether hyperscalers massive AI spending will generate sufficient returns, with concerns about customer concentration and financing structures weighing on sentiment. Bulls counter that Anthropics filing and bank-backed financing for Broadcom equipment support future demand, while others see the deals guarantees as added risk.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL immunotherapy data presented at ESMO, including early neoadjuvant colon cancer responses and sarcoma activity, are driving discussion. Bulls view the findings as promising validation, while skeptics point to small, nonrandomized studies and ongoing concerns about execution and dilution.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.00066971 USD and is down -6.50 over the last 24 hours. It is currently trading on 193 active market(s) with $8,745,522.76 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

A sharp, high-volume move in AMP has traders debating whether it marks a sustained breakout or another short-lived pump-and-dump; some also point to the Flexa payments and Anvil collateral thesis as longer-term support, though no new catalyst is clearly confirmed. Skeptics cite AMPs history of fading rallies and concerns about project execution.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is under pressure after its latest earnings despite beating expectations and raising its outlook, as traders focus on slower cloud net-new ARR growth and cautious second-half guidance. Bulls view the pullback as profit-taking after a strong run and point to continued business growth, while skeptics argue high expectations and the guidance outlook warrant a lower valuation.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results have focused attention on heavy AI infrastructure spending and its impact on cash flow, despite accelerating AWS growth that fell short of some investors expectations. Traders are split between worrying that the spending and financing burden may outweigh near-term returns and viewing the post-earnings selloff as an overreaction to strong cloud demand.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

A stronger-than-expected Q3 report and raised full-year outlook are supporting bullish attention, alongside Mercks Moderna-partnered melanoma vaccine meeting Phase 3 endpoints with Keytruda. Traders see potential oncology-platform value, but debate whether the results meet high expectations and how much upside the vaccine may add for Merck.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on the Dows relative strength versus tech-heavy indexes and possible rotation into blue-chip stocks, alongside technical support and resistance. Traders are split between expecting further gains and warning of a pullback, with rising yields, inflation concerns, and Iran-related oil risks adding to market uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Royal Caribbeans Q3 earnings beat and raised full-year outlook, supported by resilient bookings and demand, are driving attention. Many traders are bullish on the results, while others question the stocks pullback and point to fuel costs and the Sandals deal as risks.

MGM Resorts Q3 Earnings Miss Estimates on Weak Las Vegas Results

MGM's third-quarter results miss estimates as weaker Las Vegas room rates and regional profitability weigh on earnings, while China and digital businesses show resilience.

Royal Caribbean: 3 Key Takeaways for Long-Term Investors

Key PointsRoyal Caribbean invested $3 billion for a 50% Sandals stake...

Why Royal Caribbean Stock Climbed Today

Key PointsRoyal Caribbean has a plan to win market share...

Early third-quarter earnings show a 'resilient' U.S. consumer, with signs of strain

Companies from Royal Caribbean to Coca-Cola and UPS say they are seeing steady consumer spending despite high inflation...

Royal Caribbean CEO Jason Liberty on Q3 earnings beat: We're seeing an uptick in bookings

Royal Caribbean CEO Jason Liberty on Q3 earnings beat: We're seeing an uptick in bookings...

Stocks making the biggest moves midday: SoFi Technologies, Pentair, Royal Caribbean, JetBlue & more

Here are some of the companies making headlines in midday trading...

Royal Caribbean Sees No Signs of Vacation Fever Cooling As Bookings Soar

Royal Caribbean posts strong Q3 profit beat, hikes 2026 earnings outlook, and expands beyond cruises with Sandals deal.read more...

Royal Caribbean Gr Q3 2026 Earnings Call Transcript

Royal Caribbean Gr (NYSE:RCL) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzingaread more...

RCL Q3 Earnings Beat Estimates on Strong Demand, Lower Costs

Royal Caribbean's Q3 earnings beat estimates as strong close-in demand and lower costs boosted profits, prompting it to raise the 2026 earnings outlook.

Royal Caribbean (RCL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Royal Caribbean (RCL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

• Reported GAAP EPS of $6.57 up 14.26% YoY
• Reported revenue of $5.59B up 8.80% YoY
• Royal Caribbean Group expects Full Year 2026 revenue to grow 9% year over year, Net Yields to increase approximately 2.7% as-reported, and Adjusted EPS of $17.85 to $17.95.

Royal Caribbean Group reported decreased Gross Margin Yields, said expenses shifted into the fourth quarter due to timing, and identified vacation industry competition and increase in industry capacity and overcapacity as risks.

Royal Caribbean Group delivered $5.6B in Q3 revenue and $6.57 Adjusted EPS, reported mid-teens booking-volume increases, and announced a Sandals and Beaches investment expected to be immediately accretive.

Royal Caribbean Group is a cruise company, which engages in the ownership and operation of the following global cruise brands: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. The firm also holds interest in TUI Cruises GmbH, which operates the German brands TUI Cruises and Hapag-Lloyd Cruises. The company was founded by Arne Wilhelmsen in 1968 and is headquartered in Miami, FL.

Royal Caribbean Group

RCL Stock Gains 17% In A Week: Citi Drops Upside Catalyst Watch As Investors Warm To Sandals Deal 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Royal Caribbean expects the Sandals transaction to be accretive to earnings in 2027.</li><li>JPMorgan, BofA and Deutsche Bank have recently raised targets or upgraded their ratings on <a class="mention" data-mention="$RCL" data-symbol-id="RCL" href="https://stocktwits.com/symbol/RCL" target="_blank">RCL</a>.</li><li>According to Koyfin data, 22 of 29 analysts rate <a class="mention" data-mention="$RCL" data-symbol-id="RCL" href="https://stocktwits.com/symbol/RCL" target="_blank">RCL</a> 'Buy' or 'Strong Buy.’</li></ul><p>Royal Caribbean Group (<a class="mention" data-mention="$RCL" data-symbol-id="RCL" href="https://stocktwits.com/symbol/RCL" target="_blank">RCL</a>) received a fresh analyst update after Citi removed its 'upside 90-day catalyst watch' on the stock, while maintaining a 'Buy' rating and $362 price target.</p><p><a href="https://stocktwits.com/symbol/RCL">RCL shares</a> traded 2.40% higher in premarket trading on Friday at the time of writing.</p><p>According to The Fly, Citi cited <a class="mention" data-mention="$RCL" data-symbol-id="RCL" href="https://stocktwits.com/symbol/RCL" target="_blank">RCL</a>'s 17.23% rally over the past week as a reason for removing the stock from its 90-day Catalyst Watch.&nbsp;</p><p>The analyst said investors “appear to have warmed a bit” to Royal Caribbean's planned acquisition of Sandals.</p><h2 class="st-heading-2">Citi Removes Near-Term Catalyst Watch</h2><p>Citi had added <a class="mention" data-mention="$RCL" data-symbol-id="RCL" href="https://stocktwits.com/symbol/RCL" target="_blank">RCL</a> to its positive 90-day Catalyst Watch in September. According to TheFly, the earlier call cited upcoming events including Royal Caribbean's third-quarter earnings and its planned analyst day in November.</p><p>The latest action changes the Catalyst Watch status but does not alter Citi's 'Buy' rating or $362 price target, according to The Fly.</p><h2 class="st-heading-2">What Is The Sandals Deal?</h2><p>Royal Caribbean&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jp-morgan-citi-bullish-on-royal-caribbean-s-sandals-partnership/cZMJfRTRB9w">announced</a> in September that it would invest approximately $3 billion for a 50% equity interest in Sandals and Beaches Resorts. The transaction values the resort business at approximately $6 billion and is expected to close in early 2027, subject to customary closing conditions and approvals.</p><p>The investment expands Royal Caribbean's portfolio into the all-inclusive resort market. Sandals and Beaches operate resorts across the Caribbean, while Royal Caribbean's existing portfolio includes its cruise brands and other vacation experiences.</p><p>Royal Caribbean said the partnership will allow the companies to combine complementary vacation offerings while maintaining their respective operations.</p><p>Royal Caribbean expects the Sandals transaction to be accretive to earnings in 2027, according to the company's announcement. The company has secured committed debt financing from Morgan Stanley for the investment. Following completion, the joint venture will be governed by a board under the shared leadership of Royal Caribbean CEO Jason Liberty and Sandals Executive Chairman Adam Stewart.</p><h2 class="st-heading-2">Street Take On <a class="mention" data-mention="$RCL" data-symbol-id="RCL" href="https://stocktwits.com/symbol/RCL" target="_blank">RCL</a></h2><p>Recently, JPMorgan raised&nbsp;its price target on <a class="mention" data-mention="$RCL" data-symbol-id="RCL" href="https://stocktwits.com/symbol/RCL" target="_blank">RCL</a> to $394 from $345 while maintaining an 'Overweight' rating. Bank of America (BofA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rcl-stock-in-focus-wall-street-turns-bullish-on-cruise-line-operator-as-travel-demand-stays-strong/cZMjGrBRBXG">upgraded</a> <a class="mention" data-mention="$RCL" data-symbol-id="RCL" href="https://stocktwits.com/symbol/RCL" target="_blank">RCL</a> to 'Buy' from 'Neutral', while Deutsche Bank upgraded it to 'Buy' from 'Hold', according to TheFly.</p><p>According to Koyfin data, 22 out of 29 analysts covering <a class="mention" data-mention="$RCL" data-symbol-id="RCL" href="https://stocktwits.com/symbol/RCL" target="_blank">RCL</a> rate the stock 'Buy' or 'Strong Buy.'</p><h2 class="st-heading-2"><a class="mention" data-mention="$RCL" data-symbol-id="RCL" href="https://stocktwits.com/symbol/RCL" target="_blank">RCL</a>: Retail View&nbsp;</h2><p>Retail sentiment on Stocktwits was ‘neutral’ with ‘normal’ message volumes in the past 24 hours.</p><p><a class="mention" data-mention="$RCL" data-symbol-id="RCL" href="https://stocktwits.com/symbol/RCL" target="_blank">RCL</a> stock has lost about 6% year-to-date.</p><p><strong>Also read: </strong><a href="https://stocktwits.com/news-articles/markets/equity/wdc-stx-stocks-slide-up-to-10-what-s-the-toshiba-connection/cZDjXT1RBKJ"><strong>WDC, STX Stocks Slide Up To 10% — What’s The Toshiba Connection?</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Royal Caribbean's passenger cruise ship Allure of the Seas arrives at the French Mediterranean port of Marseille. (Photo by Gerard Bottino/SOPA Images/LightRocket via Getty Images)

Royal Caribbean Group (RCL) received a fresh analyst update after Citi removed its 'upside 90-day catalyst watch' on the stock, while maintaining a 'Buy' rating and $362 price target.

RCL Stock Gains 17% In A Week: Citi Drops Upside Catalyst Watch As Investors Warm To Sandals Deal

Citi had placed RCL on its positive 90-day Catalyst Watch in September ahead of the company's Q3 earnings, according to The Fly.


Track RCL stock price, charts, news and real-time market activity on Stocktwits. Join the RCL message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Royal Caribbean Group stock.

RCL Stock Price Today - Royal Caribbean Group News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$307.18
Prev Close	$310.54
Open	$307.70
Dividend Yield	1.25%
50-Day Moving Average	$271.82
Beta	1.58
Avg. Volume	3.14M
PE Ratio	18.19

52-Week High	$356.39
52-Week Low	$222.22
Market Capitalization	$82.16B
EPS (Annual)	$15.64
Price to Book	7.01
Revenue Per Employee	$166,064.82

Feed

News

Sentiment

Earnings

Fundamentals

Info

RCL Fundamentals